The Osteoarthritis Panel (OA) is a dual-marker panel for confirming degenerative joint disease and monitoring disease progression or therapy effectiveness. The OA Panel can also be used to screen for early onset of OA in high risk animals.
Hyaluronic Acid (HA) is found in the synovial fluid in joints, and is involved in the lubrication, cushioning, and support of the joint. Undamaged joints maintain HA inside the fluid, but as the joints break down, HA is leaked into the blood stream. As damage increases, so does leakage creating a viable serum marker for osteoarthritis.
Screen: Dogs at risk of OA
Diagnose: Dogs with suspected OA
Monitor: Dogs with confirmed OA
The OA panel is also used in conjunction with the Pre-Stem Cell Therapy Panel for evaluating outcomes.
Osteoarthritis is an inflammatory disease. C-Reactive Protein, the major acute phase protein in dogs, rises with the presence of an inflammatory stimulus. As the source of inflammation is resolved or managed, CRP levels will drop to normal indicating positive outcome. OA patients undergoing therapy should have a baseline CRP value for monitoring outcomes and disease progression.
Patients receiving hyaluronic acid as therapy for degenerative joint diseases should suspend treatment for 3 days (72 hours) prior to testing. Successful therapy should see a reduction in HA and CRP levels.